Autogenesis Technologies, Inc.

Other

D&d Biopharmaceuticals, Inc.

Tissue Adhesive Technologies, Inc.

Collagenesis, Inc.

Minnesota Mining and Manufacturing Company

Shanghai Qisheng Biological Preparation Co., Ltd.

C. R. Bard, Inc.

Autoimmune Inc.

Medchem Products, Inc.

Snip Holdings, Incorporated

Euclid Systems Corporation

Collagen Matrix Technologies, Inc.

Darby & Darby

Prochon Biotech Ltd.

Dale P DeVore

Charles D Kelman

Richard A Eiferman

Barbara Ann Soltz

Robert Soltz

Michael A Soltz

Braden P DeVore

Michael Luttrell

Bruce H DeWoolfson

Matthew T Scholz

Robert A Scherrer

Edwin U Keates

Chris L Davis

Jiaxun Zhu

Bruce H DeWOOLFSON

Suresh C Srivastava

Gilbert R Gonzales

David A Swann

James M Pachence

Leonard B Miller

Peter Ciarametaro

Bernard P Sullivan

Robert J Brooks

Joel D Magerman

Charles Putnam

Rory H Oefinger

Anna Gunilla Sturrock

Vance Thompson

Bruce Dewoolfson

The present disclosure relates to glycosaminoglycan-collagen copolymer compositions (such as hyaluronic acid-collagen copolymers and heparosan-collagen copolymer compositions) and medical applications thereof for augmenting soft tissue defects. The copolymer composition may be injected into tissues to correct defects or deficiencies, such as skin wrinkles, scars, and folds in dermal tissues.

Hyaluronic acid-collagen copolymer compositions and medical applications thereof

Medical devices, e.g., baffle devices, and related methods of use to administer therapeutic compositions to the eye are described. The medical device may include a body defining a lumen and including an intermediate portion that includes a compressible bellows. The device may have a flared distal end configured to contact a convex surface of the eye.

Baffle devices and related methods for delivery of therapeutic compositions to the eye

Medical devices and methods of use thereof are described. The device may include a body having a housing that defines a lumen, a piston within the housing, and an actuator operably coupled to the piston, wherein the piston is movable along the lumen by operating the actuator. The device also may include a cartridge insertable into the body and/or a flexible fitting configured for direct application to an eye of a subject.

Devices and methods for cornea treatment

The present disclosure describes a composition for cartilage defects or deficiencies repair, augmentation or treatment comprising an injectable, in situ polymerizable collagen composition and chondrocytes or stem cells in the collagen composition. The present disclosure also relates to methods for repairing or augmenting or treating cartilage defects or deficiencies using the composition and the preparation method of the composition.

Cartilage regeneration using injectable, in situ polymerizable collagen compositions containing chondrocytes or stem cells

Medical devices and methods of treating subjects using such medical devices are described. The medical device may include a housing with at least two chambers including a first chamber adjacent to a second chamber; a barrier between the first chamber and the second chamber; and a soft, flexible base. The first and second chambers may be airtight, the barrier configured to establish fluid communication between the first chamber and the second chamber upon an application of force to the barrier.

Compositions and methods for treating and imaging vulnerable plaque and other inflammatory conditions in a patient rely on the delivery of conversion electron-emitting sources and other radionuclides to regions of exposed collagen in the vasculature or other body lumens. The conversion electron-emitting sources or other radionuclides are coupled to a collagen-binding substance and administered to the vasculature or other body lumen to permit binding for imaging and/or therapeutic purposes.

Methods and therapies for treating inflammatory conditions with exposed collagen

An orthokeratological procedure is provided that prevents or retards relaxation of corneal tissue back to the original anterior curvature of the cornea. The procedure comprises applying a stabilizing agent that comprises fibril associated collagens with interrupted triple helices (FACITs) and/or small leucine-rich repeat proteoglycans (SLRPs) to the stabilize corneal tissue in a preselected shape.

Composition for stabilizing corneal tissue during or after orthokeratology lens wear

Consistent with the present invention, tissue adhesive compositions and an associated laser exposure system are provided for bonding or sealing biological tissues. The compositions are comprised of chemically derivatized soluble collagen which is formulated to concentrations ranging from 300 mg/ml (30%) to 800 mg/ml (80%) collagen protein. In particular, Type I collagen, for example, is first prepared by extraction from bovine or porcine hide and purified. The collagen preparations are then chemically derivatized with sulfhydryl reagents to improve cohesive strength and with secondary derivatizing agents, such as carboxyl groups, to improve the adhesive strength of the solder to the tissue. The compositions are then formed into viscous solutions, gels or solid films, which when exposed to energy generated from an infrared laser, for example, undergo thermally induced phase transitions. Solid or semi-solid protein compositions become less viscous enabling the high concentration protein to penetrate the interstices of treated biological tissue or to fill voids in tissue. As thermal energy is released into the surrounding environment, the protein compositions again become solid or semi-solid, adhering to the treated tissue or tissue space.

Composite tissue adhesive

Light energized tissue adhesive

Method for making a light energized tissue adhesive

Consistent with the present invention, tissue adhesive compositions and an associated laser exposure system are provided for bonding or sealing biological tissues. The compositions are comprised of chemically derivatized soluble collagen which is formulated to concentrations ranging from 300 mg/ml (30%) to 80 mg/ml (80%) collagen protein. In particular, Type I collagen, for example, is first prepared by extraction from bovine or porcine hide and purified. The collagen preparations are then chemically derivatized with sulfhydryl reagents to improve cohesive strength and with secondary derivatizing agents, such as carboxyl groups, to improve the adhesive strength of the solder to the tissue. The compositions are then formed into viscous solutions, gels or solid films which are used to encapsulate structural components such as a cojoinal network or mesh. The resultant patch which when exposed to energy generated from an infrared laser, for example, undergo thermally induced phase transitions. Solid or semi-solid protein compositions become less viscous enabling the high concentration protein to penetrate the interstices of treated biological tissue or to fill voids in tissue. As thermal energy is released into the surrounding environment, the protein compositions again become solid or semi-solid, adhering to the treated tissue or tissue space and are reinforced by the embedded cojoinal network or mesh.

Light energized tissue adhesive conformal patch

Methods are provided for processing and dispersing animal tissues that involve exposing processed (e.g., decellularized) tissue to an acylating agent, wherein the ratio of acylating agent to wet tissue weight is about 0.003:1 or less. Preferably, decellularized tissue is exposed to an amount of the acylating agent of about 0.1% to about 0.3% of wet tissue weight for a time ranging from about 30 seconds to about 10 minutes. A dispersed tissue matrix is produced that has a high degree of resistance to digestion by non-collagenase proteases, such as trypsin. In order to produce sufficiently high yields of these trypsin-resistant compositions, the processed tissue is preferably cryomilled to increase its surface area prior to acylation. The dispersed acylated decellularized tissue may be in the form of an injectable composition that can be introduced into tissue of a subject.

Processing animal tissues by decellularizing, increasing surface area and acylating

Disclosed herein are collagen films which rapidly dissolve at 35&deg; C. Also disclosed are methods for the preparation of the collagen films and their use as a vehicle for delivering a dose of therapeutic compound to a specific tissue site.

Compound delivery using rapidly dissolving collagen film

Disclosed herein is a method for treating a malignancy in an animal by introducing into the animal a radioactive isotope, or stable element subsequently made radioactive, covalently linked to a collagen. Also disclosed herein are such radiolabeled collagen compositions.

Collagen-based delivery of radioactivity for use in brachytherapy

Growing community of inventors

Chelmsford, MA, United States of America

Dale P DeVore